The US Food and Drug Administration (FDA) has expanded the approval of imbruvica (ibrutinib) for the treatment of adult patients with chronic graft-versus-host-disease (cGVHD) after the failure of one or more treatments.

The therapy is a first-in-class, oral, once-daily therapy that inhibits a protein called Bruton's tyrosine kinase (BTK).

It is jointly developed and commercialised by AbbVie company Pharmacyclics and Janssen Biotech.

cGVHD is a serious and potentially life-threatening condition that might occur in patients who receive stem cell transplant from blood or bone marrow, known as hematopoietic stem cell transplantation (HSCT).

The tissues of bone marrow recipients are attacked by bone marrow donor immune cells after they undergo an allogeneic stem cell or bone marrow transplant.

Imbruvica is currently the first and only therapy that has been approved to treat adults with cGVHD.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"This approval highlights how a known treatment for cancer is finding a new use in treating a serious and life-threatening condition that may occur in patients with blood cancer who receive a stem cell transplant."

FDA Oncology Centre of Excellence director Dr Richard Pazdur said: “Patients with cGVHD who do not respond to other forms of therapy, typically corticosteroids to suppress their immune system, now have a treatment option specifically indicated to treat their condition.

“This approval highlights how a known treatment for cancer is finding a new use in treating a serious and life-threatening condition that may occur in patients with blood cancer who receive a stem cell transplant.”

The current FDA approval is based on results from an open-label, multicentre, single-arm Phase IIb / II trial (PCYC-1129), which studied the safety and efficacy of ibrutinib in 42 cGVHD patients who failed to be treated with the first-line corticosteroid therapy and required additional treatment.

Imbruvica was previously approved for certain indications in treating chronic lymphocytic leukaemia, Waldenström’s macroglobulinemia and marginal zone lymphoma. It is also under accelerated approval status for mantle cell lymphoma.